US Bancorp DE Raises Position in Repligen Co. (NASDAQ:RGEN)

US Bancorp DE raised its stake in shares of Repligen Co. (NASDAQ:RGEN) by 1.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,222 shares of the biotechnology company’s stock after purchasing an additional 190 shares during the period. US Bancorp DE’s holdings in Repligen were worth $1,471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in RGEN. Proficio Capital Partners LLC acquired a new stake in shares of Repligen in the 4th quarter worth $3,066,000. Oppenheimer & Co. Inc. acquired a new position in Repligen in the 4th quarter worth about $216,000. Amalgamated Bank increased its stake in Repligen by 1.0% during the 4th quarter. Amalgamated Bank now owns 25,114 shares of the biotechnology company’s stock worth $3,615,000 after buying an additional 238 shares in the last quarter. Keeler Thomas Management LLC increased its stake in Repligen by 68.9% during the 4th quarter. Keeler Thomas Management LLC now owns 8,979 shares of the biotechnology company’s stock worth $1,294,000 after buying an additional 3,662 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its position in shares of Repligen by 8.9% in the fourth quarter. Handelsbanken Fonder AB now owns 14,633 shares of the biotechnology company’s stock valued at $2,106,000 after purchasing an additional 1,200 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the company. Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price target on shares of Repligen in a report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Stock Performance

NASDAQ:RGEN opened at $155.70 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a 50-day moving average of $157.23 and a two-hundred day moving average of $148.62. The stock has a market cap of $8.72 billion, a P/E ratio of -305.29, a PEG ratio of 4.54 and a beta of 0.95. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $203.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. On average, research analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.